» Articles » PMID: 11525745

Compartmentalization of Beta-secretase (Asp2) into Low-buoyant Density, Noncaveolar Lipid Rafts

Overview
Journal Curr Biol
Publisher Cell Press
Specialty Biology
Date 2001 Aug 30
PMID 11525745
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Recent epidemiological studies show a reduced prevalence of Alzheimer's disease (AD) in patients treated with inhibitors of cholesterol biosynthesis. Moreover, the cholesterol-transport protein, apolipoprotein E4, and elevated cholesterol are important risk factors for AD. Additionally, in vitro and in vivo studies show that intracellular cholesterol levels can modulate the processing of amyloid precursor protein (APP) to beta-amyloid, the major constituent of senile plaques. Cholesterol plays a crucial role in maintaining lipid rafts in a functional state. Lipid rafts are cholesterol-enriched membrane microdomains implicated in signal transduction, protein trafficking, and proteolytic processing. Since APP, beta-amyloid, and the putative gamma-secretase, presenilin-1 (PS-1), have all been found in lipid rafts, we hypothesized that the recently identified beta-secretase, Asp2 (BACE1), might also be present in rafts. Here, we report that recombinant Asp2 expressed in three distinct cell lines is raft associated. Using both detergent and nondetergent methods, Asp2 protein and activity were found in a light membrane raft fraction that also contained other components of the amyloidogenic pathway. Immunoisolation of caveolin-containing vesicles indicated that Asp2 was present in a unique raft population distinct from caveolae. Finally, depletion of raft cholesterol abrogated association of Asp2 with the light membrane fraction. These observations are consistent with the raft localization of APP processing and suggest that the partitioning of Asp2 into lipid rafts may underlie the cholesterol sensitivity of beta-amyloid production.

Citing Articles

New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease.

Cao Y, Zhao L, Chen Z, Li S Front Neurosci. 2024; 18:1430465.

PMID: 39323915 PMC: 11422391. DOI: 10.3389/fnins.2024.1430465.


Understanding Aβ Peptide Binding to Lipid Membranes: A Biophysical Perspective.

Ahyayauch H, Masserini M, Alonso A, Goni F Int J Mol Sci. 2024; 25(12).

PMID: 38928107 PMC: 11203662. DOI: 10.3390/ijms25126401.


Cholesterol-dependent amyloid β production: space for multifarious interactions between amyloid precursor protein, secretases, and cholesterol.

Rudajev V, Novotny J Cell Biosci. 2023; 13(1):171.

PMID: 37705117 PMC: 10500844. DOI: 10.1186/s13578-023-01127-y.


The Pursuit of the "Inside" of the Amyloid Hypothesis-Is C99 a Promising Therapeutic Target for Alzheimer's Disease?.

Takasugi N, Komai M, Kaneshiro N, Ikeda A, Kamikubo Y, Uehara T Cells. 2023; 12(3).

PMID: 36766796 PMC: 9914381. DOI: 10.3390/cells12030454.


Interdisciplinary Approaches to Deal with Alzheimer's Disease-From Bench to Bedside: What Feasible Options Do Already Exist Today?.

Ablinger I, Dressel K, Rott T, Lauer A, Tiemann M, Batista J Biomedicines. 2022; 10(11).

PMID: 36428494 PMC: 9687885. DOI: 10.3390/biomedicines10112922.